A controlled, parallel group, open-label, multicenter extension study to investigate efficacy and safety of oral BAY 85-3934 and darbepoetin alfa comparator in the long term treatment of anemia in pre-dialysis subjects with chronic kidney disease in Europe and Asia Pacific

Trial Profile

A controlled, parallel group, open-label, multicenter extension study to investigate efficacy and safety of oral BAY 85-3934 and darbepoetin alfa comparator in the long term treatment of anemia in pre-dialysis subjects with chronic kidney disease in Europe and Asia Pacific

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Molidustat (Primary) ; Darbepoetin alfa
  • Indications Anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DIALOGUE 3
  • Sponsors Bayer
  • Most Recent Events

    • 17 Mar 2017 This trial has been discontinued in United Kingdom.
    • 07 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 25 Jan 2017 This trial has Completed in Italy, according to the European Clinical Trials Database record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top